The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Therapeutic Nuclear Drug Market During The Forecast Period?
The therapeutic nuclear drug market has experienced rapid expansion in recent years. It is projected to grow from $2.19 billion in 2025 to $2.51 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.5%. The historical growth of this market can be linked to factors like the increasing prevalence of cancer, the early adoption of iodine-131 in thyroid disorders, the limited availability of targeted oncology therapies, the expansion of nuclear medicine departments, and the growing clinical acceptance of radiopharmaceuticals.
The therapeutic nuclear drug market size is projected to experience substantial growth in the forthcoming years. It is anticipated to expand to $4.27 billion in 2030, achieving a compound annual growth rate (CAGR) of 14.3%. This expected growth during the forecast period is driven by factors such as the development of novel therapeutic isotopes, the broadening of precision oncology approaches, increasing investments in nuclear medicine infrastructure, a rise in clinical trials for radioligand therapies, and favorable regulatory approvals for targeted nuclear drugs. Key trends anticipated in the forecast period include the increasing adoption of targeted radiopharmaceutical therapies, greater utilization of lutetium-177 and alpha-emitting isotopes, an expansion in cancer-specific nuclear drug applications, the broader implementation of combination therapies involving nuclear drugs, and a reinforced focus on safety dosimetry and regulatory compliance.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19729&type=smp
Which Drivers Are Advancing The Therapeutic Nuclear Drug Market Growth?
The expanding occurrence of cancer is expected to drive the future growth of the therapeutic nuclear drug market. Cancer is defined as a disease characterized by the uncontrolled propagation and spread of abnormal cells. The rising incidence of cancer can be attributed to factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predispositions. Therapeutic nuclear drugs serve as an important asset in combating cancer, offering targeted and effective therapeutic choices for patients by reducing tumor volume, relieving symptoms, and enhancing their quality of life. For instance, in February 2024, the World Health Organization, a Switzerland-based United Nations agency, projected that over 35 million new cancer cases would emerge by 2050. This represents a substantial 77% increase compared to the estimated 20 million cases reported in 2022. Hence, the increasing prevalence of cancer is significantly propelling the growth of the therapeutic nuclear drug market.
What Key Segment Areas Are Included In The Therapeutic Nuclear Drug Market Assessment?
The therapeutic nuclear drug market covered in this report is segmented –
1) By Type: Radium-223, Lutetium-177, Iodine-131, Other Types
2) By Distribution Channel: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes
3) By Application: Thyroid, Bone Metastasis, Lymphoma, Other Applications
Which Trends Are Influencing The Expansion Of The Therapeutic Nuclear Drug Market?
Leading firms within the therapeutic nuclear drug market are developing targeted radiotherapies, demonstrating their innovative capability for treating various tumors based on new clinical findings. These initiatives are designed to reinforce development programs, broaden the scope of therapeutic uses, and hasten the integration of advanced radiopharmaceuticals. An example is Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, which in 2025 unveiled fresh data for ATNM-400, its pioneering Actinium-225 radiotherapy, illustrating its multi-tumor potential, particularly in non-small cell lung cancer (NSCLC). These results were shared at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is engineered to provide highly effective alpha-particle therapy with precise targeting, affirming its promise as a revolutionary treatment platform for numerous solid tumors. This development underscores the industry’s dedication to expanding the clinical utility of actinium-based radiotherapies, aiming to enhance patient results and enlarge market prospects.
Which Key Players Are Active In The Therapeutic Nuclear Drug Market?
Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals
Access The Complete Therapeutic Nuclear Drug Market Report:
https://www.thebusinessresearchcompany.com/report/therapeutic-nuclear-drug-global-market-report
Which Region Has The Strongest Presence In The Therapeutic Nuclear Drug Market?
North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Therapeutic Nuclear Drug Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=19729&type=smp
Browse Through More Reports Similar to the Global Therapeutic Nuclear Drug Market 2026, By The Business Research Company
Sarcoma Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report
Drug Delivery Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report
Drug Infusion Systems Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-infusion-systems-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model